The Indian company, Eris Lifesciences, has snapped up the Zomelis trademark for vildagliptin-based formulations from Novartis AG for the Indian market, just ahead of the expiry of a key patent on the DPP-4 inhibitor.
The deal, which also covers some associated trademarks, was struck at a consideration of $13m and seemingly gives Eris a“brand name edge,” as one analyst put it, when a patent on vildagliptin
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?